Gene therapy for X-linked retinoschisis in young males
Part of Eyes & vision clinical trials.
This trial tests a single gene therapy injection under the retina for boys with X-linked retinoschisis, a condition that causes vision loss. It aims to see if the treatment is safe and can improve vision.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be male and between 5 and 18 years old
- Have a confirmed diagnosis of X-linked retinoschisis with a specific gene change (RS1 mutation)
- The study eye must have moderate vision loss (between 20/63 and 20/200), but not too severe or too good
- No prior gene or cell therapy treatments
- No active eye conditions that could interfere with the injection or study results
- No serious infections, liver problems, or immune system disorders
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gene therapy called ATSN-201 for people with X-linked retinoschisis (XLRS), a condition that affects the retina and can cause vision loss. The therapy aims to fix the faulty gene that causes the condition, potentially halting vision loss and improving vision. Participants receive a one-time injection into the eye, and the study monitors safety and effectiveness.
This trial studies whether LX103 can improve vision and is safe for people with X-linked retinoschisis (XLRS) caused by RS1 gene changes. It focuses on a specific level of vision in the study eye and checks for medical conditions that could affect eye testing or safety.
This trial tests a single injection of JWK010 gene therapy for children aged 5 to 12 with OCA1A albinism. The therapy is given into the eye to try to improve vision, and is meant for those who have not had gene therapy before.
This trial tests two doses of a gene therapy (AGTC-501) in males who already had one eye treated with a similar gene therapy for X-linked retinitis pigmentosa caused by RPGR mutations. The goal is to see if the treatment is safe and can help preserve or improve vision.
This study tests a new gene therapy called UGX202 for people with advanced retinitis pigmentosa, an eye disease that causes vision loss. The goal is to see if it is safe and if it can help improve vision.
This early study tests a gene therapy designed for people whose vision problems are caused by an RPGR genetic change. It may help slow or improve the eye disease by treating the underlying cause.
Hear when a new X-linked Retinoschisis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.